✦ LIBER ✦

P320 The presence of fistulae at baseline does not increase the incidence of adverse events in patients with Crohn's disease in the infliximab ENCORE registry

✍ Scribed by D'Haens, G.; Reinisch, W.; Colombel, J.-F.; Panes, J.; Ghosh, S.; Prantera, C.; Lindgren, S.; Hommes, D.W.; Huang, Z.; Huyck, S.; Chitkara, D.K.

Book ID: 122154036
Publisher: Oxford University Press
Year: 2014
Tongue: English
Weight: 49 KB
Volume: 8
Category: Article
ISSN: 1873-9946
DOI: 10.1016/S1873-9946(14)60441-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P013 NO NEW SAFETY SIGNALS IDENTIFIED IN

P013 NO NEW SAFETY SIGNALS IDENTIFIED IN CROHN'S DISEASE PATIENTS TREATED WITH INFLIXIMAB IN AN INTERIM REVIEW OF THE ENCORE REGISTRY

✍ J.F. Colombel; G. D'Haens; P. Rutgeerts; J. Panes; W.E. Fleig; C. Prantera; B. B 📂 Article 📅 2008 🏛 Oxford University Press ⚖ 118 KB

Smoking and surgical risk in Crohn’s dis

Smoking and surgical risk in Crohn’s disease patients treated with infliximab; does smoking increase the incidence of subsequent surgery?

✍ Andrew M. Weinberg; Faten N. Aberra; Chinyu G. Su; Gary R. Lichtenstein∗ 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 27 KB

The incidence of arthropathy adverse eve

The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab

✍ Carlo Pincelli; Eric Henninger; Florence Casset-Semanaz 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 475 KB